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ORIGINAL ARTICLE
TRUS-MR Fusion Biopsy of the Prostate: Radiological and 
Histological Correlation
Michel Lavaerts, Liesbeth De Wever, Els Vanhoutte, Frederik De Keyzer and Raymond 
Oyen
Objective: Targeted magnetic resonance/ultrasound fusion prostate biopsy has been shown to improve 
the detection of high-grade prostate cancer and to reduce sampling errors. Our objective is to assess 
MR-TRUS targeted fusion biopsy versus standard biopsy for the detection of clinically significant tumors. 
Materials and Methods: Patients were referred for abnormal digital rectal examination (DRE) or risen 
prostate-specific antigen (PSA). If an MRI-visible lesion was detected, they were included in the study. 
In total, 102 men underwent MRI followed by MR-TRUS fusion biopsy between November 2014 and Janu-
ary 2016. Tumor grading was done with the clinical relevance in mind; a cutoff was used at Gleason 7 or 
higher. Standard biopsy results were collected from clinical practice during 2005 at the same institution 
to provide baseline values.
Results: A comparable rate of prostate cancer is found whether sampling is done at random (42.4%) or 
with the use of fusion biopsy (44.1%). However, these percentages are histologically different: fewer 
low-grade tumors are detected with MR-TRUS fusion biopsy (–19.1%), while more high-grade tumors are 
diagnosed (+26%). If there is an ultrasound-visible lesion in the prostate, the gain of combined MRI and 
fusion biopsy is less impressive.
Conclusion: Fusion biopsy can provide more accurate information for optimal patient management, as it 
detects a higher percentage of high-grade prostate cancers than random sampling. Furthermore, nonrel-
evant tumors are less commonly detected using fusion biopsy.
Keywords: Fusion; Magnetic resonance imaging; Prostate biopsy; Prostate cancer; Ultrasound
Introduction
Prostate cancer (CaP) is the most commonly diagnosed 
noncutaneous cancer and second-leading cause of death in 
men [1]. Many patients with organ-confined CaP undergo 
surgical therapy or radiotherapy, especially in high-grade 
CaP. However, low-grade cancers are more commonly 
stratified toward active surveillance [2, 3]; therefore, the 
correct assessment of tumor grade is very important for 
patient management. Currently, the default assessment 
technique for the detection of CaP is based on lesion 
biopsy with histopathology. The most commonly used 
biopsy method is an at-random sampling of the entire 
organ. However, magnetic resonance imaging makes it 
possible to noninvasively assess CaP (with high sensitiv-
ity) before any invasive biopsy procedure is performed 
[3–8]. Because of this superiority of MRI imaging in lesion 
detection (compared to ultrasound), new biopsy methods 
have emerged that use this MR-obtained information dur-
ing the procedure. In this setting, the possible approaches 
can be listed as follows [6]:
1. At-random biopsy: This is the current reference 
standard. Normally, 8 to 12 cores are sampled at ran-
dom. This modality is standardized and is known for 
substantially undersampling the anterior and central 
part of the prostate, particularly in large prostates.
2. Ultrasound targeted biopsy: Whenever a lesion is 
apparent on ultrasound (US), one could selectively 
target it for biopsy. Most of the time, however, le-
sions are not visible on ultrasound, and the radiolo-
gist is forced back to option 1. In clinical practice, 
the radiologist usually combines at-random biopsies 
with targeted biopsy whenever possible.
3. “Cognitive fusion”: Even without dedicated fusion 
systems, prior MR imaging information can be used 
in the biopsy procedure. A trained practitioner is 
able to mentally “fuse” the MR information with the 
ultrasound images by identifying landmarks that are 
visible on both modalities. This is a method that is 
very operator- dependent.
4. TRUS-MR targeted fusion biopsy: This modality 
combines the superior diagnostic accuracy of MR 
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imaging with the cost-effectiveness of transrectal 
US biopsy. The MRI images are superimposed on 
the TRUS images. The practitioner is able to take 
samples in predefined lesions. 
5. In-gantry “direct” MR-guided biopsy: This is the only 
method that does not make use of ultrasound imag-
ing. Because time on the MRI is still quite expensive, 
we think this time-consuming method is not yet 
ready for daily applications in CaP detection. 
Comparison between literature reports is limited due to 
the variety of possible approaches and to the practition-
er’s experience in these approaches (i.e., cognitive fusion). 
In this work, we will focus solely on the TRUS-MR fusion 
biopsy (approach 4) compared to the reference standard 
of at-random biopsies (approach 1).
The main purpose of this study is to examine whether a 
TRUS-MR fusion apparatus is beneficial to the outcome in 
CaP detection. More specifically, does fusion lead to detec-
tion of more clinically relevant and fewer low-grade tumors?
Secondary questions are whether there are means 
to reduce sampling errors. Or is there a lesion-volume 
threshold below which the accuracy of the fusion appara-
tus is insufficient? 
Materials and Methods
Population
Patients in this study were men with elevated PSA or an 
abnormal DRE with at least one lesion in the prostate on 
MRI. They were prospectively enrolled at UZ Leuven, Bel-
gium, in a clinical trial with ethical commission approval 
(registration number: mp07480). Enrollment occurred 
between November 2014 and January 2016 with writ-
ten informed consent (15-month period). More than half 
(51,5%) of all included patients had had prior negative at-
random biopsies. One must note that this is just a mere 
finding; this had nothing to do with our inclusion criteria. 
For a lot of patients, their initial investigation was in fact 
the MRI included in this study. All data was retrospectively 
analyzed in the framework of this master paper.
Inclusion criteria
Every patient with lesions on MRI was included. Those 
without lesions received at-random biopsies and were 
excluded from this study (their outcome is outside the 
scope of this fusion-oriented study). Individual patient 
inclusion was decided on a per-case basis by the attend-
ing radiologist, without fixed lesion volumetric threshold 
in the beginning. Approximately halfway through the 
study, we had the impression that the very small (< 0.2 cc) 
regions of interest (ROI) nearly always seemed to be histo-
logically insignificant. The study inclusion criteria—for a 
lesion—was therefore altered to only include larger (> 0.2 
cc) lesions on MRI, most of which are still really small. Half 
of the ROIs measured less than 0.4 cc, of which most were 
sampled in the beginning of the study. Only 25 percent 
of the ROIs measured more than 1.9 cc. Exclusion criteria 
were prior prostate surgery or cancer therapy and contra-
indication to MRI in general. 
Methods
Imaging Protocol
All patients underwent MRI on a Siemens Magnetom 
Aera 1.5 Tesla system for a total scan time of around 
15 minutes. We used an 18 phased-array body coil. The 
T2 sequences (Table 1) are used to localize and view 
the prostate anatomy as well as stage possible tumoral 
lesions. Because inflammation can mimic CaP, diffusion-
weighted images (DWI) were added to identify possible 
malignant ROIs [9]. DWI quantifies free water movement, 
known as “Brownian” motion. In tumoral lesions, the 
increased cellularity reduces the water mobility, leading 
to “restricted diffusion,” which is characterized by a low 
apparent diffusion coefficient (ADC) [10, 11]. The degree 
of diffusion restriction is known to correlate with the 
Gleason score, probably reflecting that same cellular-
density aspect [12, 13]. One T1 sequence was added to 
rule out previous biopsy damage (and as such rule out 
false-positive results). Lesions on MRI were delineated 
by a radiologist, assigned a grade of CaP suspicion, and 
imported into the fusion system for biopsy using the Pro-
Fuse software.
Biopsy Protocol
The Artemis device (Eigen, Grass Valley, CA) is a 3D ultra-
sound-guided prostate biopsy system that provides track-
ing of MR-identified ROIs within the prostate on MR-
imagery fused with real-time ultrasound [15] (Figure 1). 
The radiologist who delineated the ROIs on the MRI images 
was the same physician that performed the biopsy. 
A prophylactic antibiotic was given, and the procedure 
was conducted with the patient in left lateral decubitus. 
Parallel imaging technique: Grappa, Factor 2
T1/T2 Orientation Acquisition 
time
Pixel size  
in mm.
# slices Field of  
View (mm)
Slice thickness 
(mm)
Repetition 
time (ms)
Echo Time 
(ms)
T2 Sagittal 1:49 0.6*0.6 26 260 * 260 3.5 7700.0 133.0
DW Transversal 5:47 2.7*2.7 42 350 * 285 4.0 9900 67.0 
T2 Transversal 5:05 0.6*0.6 56 260 * 236 3.0 11250.0 124.0
T2 Coronal 2:50 0.6*0.6 40 260 * 260 3.5 14010 124.0
T1: fat  
suppression
Transversal 0:18 1.0*1.0 52 320 * 260 3.0 4.26 2.09
Table 1: Imaging protocol.
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The prostate was anesthetized with a peri-prostatic block. 
The radiologist then made a complete axial transrectal 
ultrasound volume sweep of the prostate and outlined the 
outer contours on the fusion system (Figure 2). The pro-
cess of acquiring the US sweep, delineating the prostate 
margin, and calculating the software fusion takes around 
5 minutes, while the biopsy procedure itself, on average, 
took 15 minutes. Sampling was done with a conventional 
spring-loaded gun inserted in the fusion apparatus. A rec-
alibration of the fusion images was done each time the 
patient had moved. 
The procedures were executed by one of three 
 radiologists from the same hospital, with 2 (EVH), 10 
(LDW), and 30 years (RO) of experience in genitourinary 
radiology.
In this study, only biopsies were taken of the ROIs which 
we had previously outlined on the MRI images (Figure 3). 
There was (mostly) no concomitant at-random biopsy 
performed.
Comparison
In 2005, there had been a study at our institution on at-
random sampling of the prostate. We wanted to compare 
our current results of fusion biopsy with the at-random 
results of that study. Although inclusion criteria are very 
similar in both studies (risen PSA and/or abnormal DRE), 
it is important to note that, in 2005, patients were not 
screened yet on MRI, so no information was available on 
whether any lesions were visible on MRI. This could lead 
to a slightly different inclusion bias. 
Statistical analysis
Each lesion was identified as a separate ROI with a spe-
cific histological outcome (Figure 4: database). In patients 
where more than one tumor focus was found, the highest 
Gleason score was reported.
Analysis was done by a statistician of the department 
of bio-statistics at UZ Leuven. The Spearman correlation 
was calculated as a measure of association between two 
continuous or ordinal variables. The Mann-Whitney U test 
was used for testing the difference between two groups 
on continuous or ordinal variables. Further logistic regres-
sion models were used to analyze binary outcomes as well 
as proportional odds models for ordinal outcomes. The at-
random results of 2005 were compared with the current 
fusion results using the chi-square test. All tests are two-
sided, and a 5 percent significance level is assumed for all 
tests. Analysis was performed using the SAS software (ver-
sion 9.4 of the SAS System for Windows).
Two Different Risk Stratifications Were Used
The first risk stratification was to compare our results 
with our own at-random database from 2005. Here we’ve 
chosen to look solely at the Gleason scores. This risk 
Figure 1: Artemis Eigen Fusion system [14].
Figure 2: Outlining of the prostate on the Artemis system.
Figure 3: Precise sampling of a ROI [25].
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 stratification is the most relevant for patient management 
and outcome. Clinically, the Gleason scores of 7 or higher 
are of real significance [2, 3, 16]. We therefore subdivided 
our patients in clinically “high-grade tumor” (above Glea-
son score of 6) or “low-grade tumor” (below or equal to 
Gleason score of 6) groups. 
The second risk stratification used was to compare our 
results with the well-known JAMA study by Siddiqui et 
al. [17] in which “low-risk JAMA” on biopsy was defined 
as Gleason score 6 or low-volume Gleason score 3+4 (i.e., 
< 50% of any core containing cancer); “intermediate-risk 
JAMA” was defined as Gleason score 3+4 with 50 percent or 
more of any core positive for cancer; and “high-risk JAMA 
tumors” were defined as Gleason score 4+3 or greater.
Results
Per-patient Results
Patients included in the study were 102 men aged 52–80 
(66.2 ± 6.5 years), with a mean PSA of 9.5 µg/l ± 6.2 µg/l) 
(Table 2). The median time between MRI and biopsy was 
23 days (range: 0–210 days). 
Regarding the PSA relation to patient age, Spearman cor-
relation showed that PSA increases significantly with patient 
age (p = 0.006). Whether or not carcinoma was found 
showed no significant correlation with the absolute PSA 
value (p-value = 0.34) nor with patient age (p-value = 0.43).
A slight majority (51.5%) of patients had had prior at-
random biopsies that were all histologically negative. If a 
patient underwent more than one fusion-guided biopsy, 
only the first session was evaluated in our analysis. 
In our study, 55.9 percent of patients had no focus 
of tumor, while 44.1 percent did test positive for CaP 
(Figure 5).
Per-lesion Results
In total, 341 regions of interest (ROI) were outlined and 
sampled in 102 patients, and, on average, 2.4 biopsies 
(±1.45) were taken per ROI. Of the 341 ROIs that were 
biopsied, 80 were found histologically positive for ade-
nocarcinoma, and 261 samples tested negative on carci-
noma, of which 70.9 percent showed one or more benign 
cause. When benign cause was identified, it was mostly 
attributed to atrophy, inflammation, hyperplasia, or a 
combination of these (Figure 6).
Higher Detection Rate Of High-Grade Tumors, Fewer 
Detection Of Low-Grade Tumors
In 2005, we biopsied 303 men at random that had ultra-
sound-visible lesions in the prostate and 381 men that 
had no ultrasound visible lesion. Only the truly at-random 
biopsy results are included in our comparison. To be clear, 
there was no US-targeted biopsy result included, not 
even when lesions were visible on ultrasound (Figure 7 
+ Table 5).
Fusion Biopsy versus “At-random Biopsy When No Lesion Is 
Visible on Ultrasound”
We have found 18.6 percent less low-grade tumors with 
fusion biopsy and 68.7 percent more high-grade tumors 
(p-value of 0.01) compared to the at-random biopsies 
from 2005 where no lesion was seen on ultrasound.
Figure 4: Study database set-up.
Variable Statistic All
Age N 102
Mean 66.2
Std 6.56
Median 67.5
IQR (61.0; 71.0)
Range (52.0; 80.0)
PSA N 102
Mean 9.5
Std 6.23
Median 7.1
IQR (5.8; 11.8)
Range (1.1; 38.0)
Prostate Volume N 102
Mean 5837.3
Std 58305.12
Median 60.5
IQR (40.1; 80.7)
Range (4.9; 588917)
Prior Biopsy
No n/N (%) 48/99 (48.48%)
Yes n/N (%) 51/99 (51.52%)
Tumor risk group  
(according to JAMA article)
No tumor n/N (%) 57/101 (56.44%)
Low risk n/N (%) 21/101 (20.79%)
Intermediate risk n/N (%) 9/101 (8.91%)
High risk n/N (%) 14/101 (13.86%)
Highest Gleason score
No tumor n/N (%) 57/102 (55.88%)
3 n/N (%) 1/102 (0.98%)
6 n/N (%) 16/102 (15.69%)
7 n/N (%) 20/102 (19.61%)
8 n/N (%) 7/102 (6.86%)
9 n/N (%) 1/102 (0.98%)
Table 2: Patient demographics.
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Fusion Biopsy versus “At-random Biopsy When a Lesion Is 
Visible on Ultrasound”
With fusion biopsy, we detect 19.8 percent fewer low-grade 
tumors and 4 percent fewer high-grade tumors compared 
to the at-random biopsies of 2005 where ultrasound visible 
lesions were seen. In that group, the fusion biopsy results 
are inferior compared to the at-random sampling results. 
We do know, however, that lesions that are visible on ultra-
sound have a higher chance of being malignant [18].
When all at-random cases of 2005 are combined, fusion 
biopsy finds 19.1 percent less low-grade tumors and 26.0 
percent more high-grade tumors compared to the at-ran-
dom technique. 
One can notice an increase in detection somewhere 
halfway in our study (p-value: 0.0643) (Figure 8), around 
the time the patient selection criteria were altered (we 
stopped sampling lesions < 0.2 cc). 
Biopsy procedures were performed by three different 
physicians that each accounted for 9 percent (RO), 39 per-
cent (LDW), and 52 percent (EVH) of the interventions. No 
significant differences were observed in terms of outcome 
between practitioners (p-value: 0.1374). One must note 
that the relatively small population makes it difficult to 
definitely rule out inter-observer variance.  
No statistical significant correlation was found between 
ROI volume (nor ROI volume %) and the histological out-
come (p-value 0.0967 and 0.5285, respectively). 
Discussion
In this study, targeted biopsy significantly increased the 
detection of clinically significant tumors (> Gleason score 
6), and fewer low-grade tumors were detected. 
A higher detection rate of high-grade tumors will lead 
to more clinically relevant information for the urologist’s 
Figure 5: Fusion cancer detection rate per Gleason score 
(in percentages).
Figure 6: Benign causes of diffusion restriction.
Figure 7: Fusion biopsy versus at random sampling.
Figure 8: Frequency of carcinoma detection.
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daily practice. This implies better sensitivity and specific-
ity of the detection modality and is therefore beneficial for 
patient management. If high-grade tumors are detected 
earlier, the gain in time will be translated into an ear-
lier start of therapy. Patients with a Gleason score above 
6 will more likely be accurately detected and, therefore, 
less likely be mistakenly stratified toward active surveil-
lance because of suboptimal samples. Because of higher 
specificity, when biopsy returns negative, there will be less 
need for resampling or early follow-up, and, in the end, 
fewer MRI scans will be necessary. 
Low-grade tumors (≤ Gleason score 6) are most often not 
treated immediately because it has been shown that CaP 
mortality (at 7 years) is not significantly different between 
immediate radical prostatectomy and active surveillance 
[2, 3]. Therefore, the lower detection rate of low-grade 
tumors with fusion biopsy is not necessarily a negative find-
ing and might even be called positive as it avoids unneces-
sary treatment and limits patient anxiety. In patients with 
multiple lesions, this approach also allows to minimize the 
required number of biopsy cores by only focusing on the 
lesions with the highest (expected) Gleason score.
Adding standard biopsy to targeted biopsy, according 
to Siddiqui et al. [17] leads to a 22 percent higher detec-
tion rate of cancer. However, 83 percent of these are low 
risk, while only 5 percent are high risk. This equates to the 
need to biopsy 200 men to diagnose 1 additional high-risk 
cancer. Differently stated, to obtain 1 additional high-risk 
tumor, 17 additional cases of low-risk cancer would be 
diagnosed. The incorporation of standard biopsy in addi-
tion to targeted biopsy led to no change in Gleason score 
risk stratification in 85 percent of patients in their study. 
Therefore, one can state that no concomitant at random 
biopsy needs to be performed.
The detection rate went up during our study, even 
though experience with the biopsy system is one attribut-
ing factor to that effect; the main cause is the change of 
inclusion criteria midstudy (Figure 8). Most small lesions 
came back negative, which gave us the idea that they were 
too small to sample precisely. It made us question the 
accuracy of the approach. Because of the size of our study, 
we can only conclude that there is an increased detec-
tion rate over time with a significant leap upward when 
the inclusion criteria became more stringent. However, 
the current data is not sufficient to estimate the optimal 
 volume threshold for successful biopsy. 
A study from 2011 tracked biopsy accuracy in 11 con-
secutive men by removing, detaching, and cleaning the 
ultrasound probe after biopsy was done and then rein-
stalling the complete setup while the patient remained 
still. They then re-biopsied three randomly selected sites 
in each patient, and the distance between original and 
re-biopsy sites was determined. The mean error for all 
32 biopsies was 1.2 ± 1.1 mm (range 0.2–5.1) and was 
independent of prostate volume or biopsy location [19]. 
This might seem very accurate, but it needs some extra 
explanation. 
These numbers represent solely the accuracy of repeat-
ing biopsies in the same lesions. This error rate stands side 
by side with the already existing error margin made by the 
fusion process itself (which is multifactorial: time between 
MRI and biopsy procedure, operator delineating experi-
ence and proficiency, patient movement). Therefore, we 
advise to not sample the millimetric lesions, as accuracy 
cannot be guaranteed (yet).
If a lesion is visible on ultrasound, the differences 
between at-random biopsies and fusion biopsies is neg-
ligible. With fusion, we detected slightly fewer low-grade 
tumors and fewer high-grade tumors compared to at-
random sampling ultrasound-visible lesion prostates. It 
seems, therefore, that a fusion biopsy should no longer be 
performed if an ultrasound-visible lesion is detected and 
the practitioner is certain that it is the same lesion as seen 
on MRI. In that case, solely ultrasound targeted and at-
random biopsy will suffice. If the practitioner is not sure 
whether it is the same lesion as seen on MRI, it seems pru-
dent to complete the fusion biopsy as well as the visually 
targeted and at-random biopsy to obtain optimal results. 
No significant differences were seen in our study 
between the observed frequencies of tumors per segment; 
however, a tendency exists that more tumors originate 
from locations outside of the transition zone (Table 3). 
This same trend was seen when compared to the study of 
2005 (Table 4). Both studies are comparable in terms of 
where tumors originate from.
Reducing sampling errors
Adequate loco-regional anesthesia is very important to 
reduce sampling errors. Low patient pain will lead to less 
movement and a higher biopsy accuracy, as each (signifi-
cant) patient movement forces the radiologist to perform a 
recalibration step in the fusion system. Each recalibration 
step increases the total procedure time, which decreases 
anesthesia efficacy and increases patient discomfort and 
mobility. Because of this, a total recalibration after each 
movement is practically impossible, and patient move-
ment will therefore lead to inaccuracy.
Current literature
The idea that more high-grade and fewer low-grade CaP is 
detected by fusion biopsy is made fact by a study published 
in Oncotarget in August 2015. This study is a meta-analysis 
of 16 paired cohort studies by Wu et al. [20]. They com-
pared all known targeted-fusion biopsy articles available 
Right-TZ Right-nTZ Left-TZ Left-nTZ
22.37% 
(17/76)
27.63% 
(21/76)
19.74% 
(15/76)
30.26% 
(23/76)
Table 3: 2015 Fusion biopsy: observed frequencies of 
tumors per segment (transition zone TZ versus non-
transition zone nTZ).
Transition zone Non-transition zone
US-visible lesion 41.44% 58.55%
No US-visible lesion 41.84% 58.15%
Table 4: 2005 At random biopsy: observed frequencies of 
tumor detection per segment.
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Figure 9: Our fusion results versus their at random/
fusion results.
to date (before August 2015). There were a total of 3,105 
patients studied. It showed that MR-TRUS fusion biopsy 
detects more clinically significant cancers than systematic 
biopsy with great statistical significance (RR = 1.19; p-value 
< 0.05). We had the same conclusions with comparable 
outcome in terms of percentages.
One of the main contributors to this meta-analysis was 
the study performed in 1,003 patients by Siddiqui et al. 
When we compare our data using the same risk strati-
fication (see chapter “Statistical Analysis”) as they had 
used in their study, we could categorize 19.6 percent in 
the low-risk JAMA group, 9.8 percent in the intermedi-
ate-risk JAMA group, and 13.7 percent in the high-risk 
JAMA group. Below is a graphical comparison of these 
results (Figure 9). To compare with the JAMA study, one 
patient was excluded from the calculations because of the 
unknown carcinoma percentage in a lesion. The limitation 
of this comparison is that we were not able to include our 
own at-random results in this graph because, in 2005, we 
had not included lesion size in our database, so the per-
centages in the next paragraph will be our results in cor-
relation to their at-random cases.
They found 17.5 percent fewer low-risk carcinomas, 
while we found 23.7 percent fewer low-risk CaP. And 41.5 
percent more high-risk tumors were diagnosed in the 
JAMA article, while we had a mere 12.9 percent increase 
in high-risk tumor detection. 
The reason these numbers vary is presumably multifac-
torial, related to differences in inclusion criteria and the 
number of included patients. While our results are a bit 
different than theirs, especially due to the lower preva-
lence of higher Gleason scores in our study, the same 
trend was found in both studies: fewer low-risk tumors 
were detected, and more high-risk tumors were diagnosed. 
Limitations
The main limitation in our comparison with the at-ran-
dom results of 2005 is that, back then, there was no MRI 
screening indication for the prostate, so even the people 
without lesions were biopsied. That means that the results 
of this study represent a combined effect: the efficiency of 
fusion biopsy as well as the lesion detection of MRI. On 
average, the JAMA study showed that around 15 percent 
of people that underwent MRI showed no lesions [17]. We 
were not able to verify this for our own population.  How-
ever, we can expect comparable numbers at our institu-
tion (because of the size of their study). Not performing 
an at-random biopsy in the cases where MRI did not show 
a lesion is justified by the fact that the negative predictive 
value of a negative MRI is 98 percent for a Gleason score 
Gleason score Modality Result 2005:  
at random sampling
Result 2015:  
Fusion biopsies
P-value
All without US lesion 140/381 (36.75) 45/102 (44.12) 0.1737
All with US lesion 150/303 (49.50) 0.3463
All all at random (sum) 290/684 (42.40) 0.7432
G<=6 without US lesion 78/381 (20.47) 17/102 (16.67) 0.3904
G<=6 with US lesion 63/303 (20.79) 0.3654
G<=6 all at random (sum) 141/684 (20.61) 0.3534
G>6 without US lesion 62/381 (16.27) 28/102 (27.45) 0.0100
G>6 with US lesion 87/303 (28.71) 0.8069
G>6 all at random (sum) 149/684 (21.78) 0.2012
P-values from chi-square test
Table 5: Comparison with the at random results from 2005.
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7 lesion or higher, the same cutoff we used in our study 
[21]. So although the MR-inclusion criteria causes a bit of 
a bias, the same trend toward a higher detection of high-
grade tumors remains. 
Prostate MRI was performed without endorectal coil 
(ERC). The current PIRADS version 2 guidelines state that 
contemporary 1.5 T scanners that employ a relatively 
high number of external phased array coil elements and 
RF channels (16 or more) “may be capable of achieving 
adequate signal-to-noise ratio in many patients without 
an ERC.” Because our equipment complied to these crite-
ria as well as patient comfort, this study was performed 
without ERC [22].
One other limitation might be that we did not perform 
multiparametric MRI (MP-MRI), which implies the use of 
at least two functional imaging techniques. Mostly DWI as 
well as dynamic contrast-enhanced sequences (DCE) are 
then used. We only performed T2-weighted (T2W) imaging 
in combination with DWI. However, the detection rate is 
significantly higher for T2W + DWI than that for T2W + DCE 
or the three sequences combined. Especially in the transi-
tion zone, the MP-MRI model fails to improve the detec-
tion rate compared to T2W and DWI sequences alone [23]. 
Therefore, conducting a complete MP-MRI protocol was, in 
our understanding, of no additional value in this study.
Even though all previously listed findings translate into 
great clinical benefits, it is important to recognize that this 
study is preliminary toward prostate cancer–specific mortality. 
The cost and net benefit of giving every patient an MRI 
as well as fusion biopsy needs to be investigated in fur-
ther studies. There is however a study that investigated in-
gantry MR-biopsy that concluded that when the benefits 
of MRI were considered, the expected costs per patient, in 
the end, were virtually the same [24].
Conclusion
Fusion biopsy significantly increased the detection rate of 
clinically significant tumors and decreased the detection 
rate of low-grade tumors. A higher detection rate of high-
grade tumors will lead to more clinically relevant informa-
tion and is therefore beneficial for patient management. 
If high-grade tumors are detected earlier, the gain in time 
will be translated into earlier therapy. Because of higher 
specificity, there will be less need for resampling and less 
need for early follow-up. 
The lower detection rate of low-grade tumors might be 
called positive as it avoids unnecessary treatment and lim-
its patient anxiety. In patients with multiple lesions, this 
approach also allows us to minimize the required number 
of biopsy cores by only focusing toward the lesions with 
the highest (expected) Gleason score.
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